Kirsten Castillo, AWESOME’s VP of Member Engagement, has been named to the board of Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases.
In announcing the news, the Chairman and CEO of Ocugen, Shankar Musunuri, Ph.D, said that Kirsten and Ocugen’s other new board member, Prabhavathi Fernandes, Ph.D. “bring a wealth of leadership experience and knowledge to our board. Their expertise will be tremendously valuable as we prepare for topline data from our Phase 3 clinical trial for OCU300, our product candidate for the treatment of ocular Graft Versus Host Disease (oGVHD), and prepare to advance our breakthrough modifier gene therapy platform into the clinic in 2021.”
Kirsten brings 20 years of supply chain and logistics experience to her role as board member and said, “Ocugen has a compelling pipeline of transformative eye therapies and I am excited to join this talented board in leading the continued growth of the company. I look forward to bringing my leadership expertise in advancing these therapies towards the goal of reaching patients in need.”
Before joining the AWESOME leadership team in 2019, Kirsten was CEO of her family-owned transportation and logistics services company — Logistics Planning Services (LPS). After GlobalTranz Enterprises acquired LPS in 2017, Kirsten served as GlobalTranz COO through the transition.